ResMed’s earnings rise as cash generation supports over $1 billion of shareholder returns

ResMed ($RMD) reported approximately $1.4 billion of revenue for the first quarter of fiscal 2027, up 6%, as demand for sleep devices, masks and accessories increased. Adjusted earnings per share rose 14% to $2.91, while GAAP EPS increased 23% to $2.92. Adjusted gross margin improved by half a percentage point to 62.5%, helped by productivity gains across the sleep and breathing-health business.

Operating cash flow reached $422 million and free cash flow was $374 million. Cash generation and proceeds from the MatrixCare disposal supported more than $1 billion in combined repurchases and dividends during the quarter. ResMed retained its fiscal 2027 revenue forecast of $5.75–$5.85 billion and adjusted EPS range of $12.00–$12.25. The outlook is unchanged, and reported revenue growth differs from the 7% increase measured on a core constant-currency basis.

Sources:

• investor.resmed.com
• gem.marketminute.com